Introduction: The Growing Need for Purification Efficiency

The global demand for biologic medicines, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies, continues to accelerate. As pipelines expand and manufacturing scales increase, purification — traditionally a bottleneck in downstream processing — must keep pace. Continuous chromatography has emerged as a transformative approach, enabling faster cycles, higher yields, and more consistent product quality. This article examines the latest advances in continuous chromatography and their impact on biologics purification workflows.

What Is Continuous Chromatography?

Continuous chromatography refers to separation processes in which the mobile phase and stationary phase are in constant motion relative to each other, allowing the feed to be introduced and product collected without interruption. Unlike traditional batch chromatography, where a fixed volume of feed is processed, the column is regenerated, and the cycle repeats, continuous systems operate in a steady state, often using multiple columns in a rotating or sequential configuration.

The most common implementations are simulated moving bed (SMB) and periodic counter-current chromatography (PCCC). In SMB, a series of columns are connected in a loop, and the inlet and outlet ports are switched periodically to simulate counter-current movement of the solid phase. PCCC uses a smaller number of columns with a cyclic sequence of loading, washing, elution, and regeneration steps, achieving near-continuous operation. More recent multi-column systems, such as CaptureSMB and BioSC, are designed specifically for biologics capture and polishing.

Historical Context: From Batch to Continuous

Batch chromatography has been the cornerstone of bioprocessing for decades. While reliable, batch methods suffer from downtime between cycles, inefficient resin utilization, and variable product quality due to column aging. The shift toward continuous processing gained momentum in the late 1990s and early 2000s, driven by advances in resin technology and process control. Early adopters in the pharmaceutical industry demonstrated that continuous systems could reduce purification times by 50–80% while improving yield and purity. Today, continuous chromatography is a key enabler of integrated continuous biomanufacturing, which the FDA and other regulatory bodies encourage through initiatives such as Quality by Design (QbD) and Process Analytical Technology (PAT).

Recent Technological Advances

Advanced Resin Technologies

The heart of any chromatography system is the resin. Recent innovations have produced materials with higher binding capacities, faster mass transfer, and improved chemical stability. Core-shell particles, for example, feature a non-porous core surrounded by a porous shell, reducing diffusion path lengths and enabling higher flow rates without sacrificing resolution. Membrane adsorbers and monoliths offer similar benefits by eliminating diffusional limitations entirely. These materials are particularly valuable for large molecules, such as viruses and plasmid DNA, where traditional resin pores restrict access.

Additionally, engineered protein A ligands with enhanced alkaline stability allow for more aggressive cleaning-in-place (CIP) protocols, extending resin lifetime and reducing cost per gram of product. Mixed-mode resins that combine ion exchange and hydrophobic interaction properties provide orthogonal selectivity in a single step, simplifying process design.

Automation and Process Control

Modern continuous chromatography platforms integrate real-time monitoring and closed-loop control using sensors for UV absorbance, pH, conductivity, and temperature. Process analytical technology (PAT) tools such as in-line UV-Vis, near-infrared (NIR) spectroscopy, and Raman spectroscopy provide continuous data on product concentration and impurity levels. This data feeds into model-based control algorithms that adjust flow rates, column switching times, and elution gradients automatically, minimizing operator intervention.

Machine learning and artificial intelligence are beginning to play a role, with algorithms that predict breakthrough curves and optimize column loading in real time. These advances reduce the risk of resin overloading and product loss, while ensuring consistent output even when feed quality varies.

Modular and Single-Use Systems

Flexibility is critical in a landscape where multiproduct facilities are common. Modular continuous chromatography systems can be configured with varying numbers of columns and column sizes, allowing rapid changeover between different molecules. Single-use flow paths, including pre-sterilized columns, tubing, and connectors, eliminate the need for cleaning validation and reduce cross-contamination risks. For contract manufacturing organizations (CMOs) and biotech startups, single-use systems lower capital expenditure and accelerate timelines from process development to commercial production.

Process Intensification: Multi-Column and Integrated Designs

Multi-column continuous chromatography systems have evolved from lab-scale curiosities to production-ready platforms. Systems like the CaptureSMB (from ChromaCon/Novo Nordisk) and the BioSC (from NOVASEP/Sartorius) use two to eight columns in a synchronized sequence to maximize resin utilization and throughput. These systems can achieve binding capacities close to static binding capacity by operating at lower linear velocities during load, minimizing the loss of product in the flow-through.

Further intensification involves coupling continuous chromatography directly with upstream perfusion bioreactors. In such integrated continuous processes, the harvested cell culture fluid flows directly into the capture step without intermediate hold tanks. This reduces product degradation due to enzymatic activity or aggregation and shortens overall residence time from cell culture to purified bulk.

Benefits of Continuous Chromatography

Faster Purification Cycles

By eliminating idle time between batch cycles, continuous chromatography can reduce total purification time by 50–80%. For a typical monoclonal antibody process, a batch capture step might take 6–8 hours per cycle, while a continuous multi-column system can process the same volume in 2–3 hours. This acceleration is critical for time-sensitive applications such as pandemic vaccine production or personalized cell therapies.

Higher Product Quality

Consistent operating conditions in continuous chromatography minimize the variability that arises from column aging, feed composition fluctuations, and operator differences. Aggregation and fragmentation levels are often lower in continuous processes because product is eluted promptly after loading, reducing exposure to harsh elution conditions. Additionally, the ability to operate at lower linear velocities during load reduces shear stress on fragile molecules, such as enveloped viruses or fusion proteins.

Cost Efficiency

Continuous chromatography improves resin utilization from typical batch levels of 60–70% up to 90% or more. This translates directly into lower resin costs per gram of product. Buffer consumption can also be reduced because columns are regenerated more efficiently in a continuous sequence. Labor costs decrease as automation takes over routine operations, and the smaller equipment footprint of continuous systems can reduce facility construction costs.

Scalability and Flexibility

Modular continuous systems scale linearly by adding more columns or increasing column diameter. Process development is streamlined because the same operating principles apply from bench to commercial scale. For facilities that need to produce multiple products, the ability to quickly swap column chemistries and reprogram sequences enables rapid changeover.

Impact on Biologics Manufacturing

The adoption of continuous chromatography is reshaping how biologic drugs are developed and produced. For established products such as monoclonal antibodies, manufacturers are retrofitting existing plants with continuous capture steps to increase capacity without major capital investment. In the vaccine sector, continuous purification played a role in the rapid scale-up of mRNA and viral vector vaccines during the COVID-19 pandemic. Process development timelines were shortened from months to weeks, demonstrating the agility that continuous processing provides.

Regulatory agencies have shown increasing acceptance of continuous processes. The FDA’s 2019 guidance on “Continuous Manufacturing of Drug Substances and Drug Products” provides a framework for validation and control. Several approved biologics now use continuous chromatography in their commercial processes, and the number is expected to grow as more companies adopt end-to-end continuous manufacturing.

A comprehensive review of continuous chromatography applications published in Biotechnology Advances highlights case studies where continuous capture improved yield by 15–30% and reduced buffer consumption by up to 40% compared to batch operations. Another study from the National Institute for Bioprocessing Research and Training (NIBRT) demonstrated that continuous polishing steps could achieve impurity clearance equivalent to batch processes with fewer columns and less resin.

Challenges and Considerations

Despite its advantages, continuous chromatography is not a plug-and-play replacement for batch. System complexity is higher, requiring robust process control and thorough qualification. Validation of continuous processes demands a different mindset: rather than testing discrete batches, manufacturers must ensure that the system operates in a state of control over extended periods. Leachables and extractables from single-use components, as well as the risk of microbial ingress during long runs, must be carefully managed.

Initial capital investment for multi-column systems can be significant, although total cost of ownership often favors continuous when factoring in resin savings and increased throughput. Training operators and process engineers on continuous principles is essential, as is the availability of skilled personnel. Nonetheless, the industry is rapidly closing these gaps through collaborative efforts between equipment vendors, biopharma companies, and academic institutions.

Future Perspectives

Digital Twins and AI-Driven Optimization

The integration of digital twins — virtual replicas of the physical chromatography system — will allow process engineers to simulate and optimize column sequences, loading strategies, and cleaning cycles without costly experimental iterations. Coupled with AI-based predictive models, these tools can forecast resin lifetime, detect anomalies, and recommend adjustments in real time. The goal is a fully autonomous purification train that self-optimizes for maximum yield and quality.

Next-Generation Resins and Adsorbents

Research into smart resins that change their binding properties in response to stimuli (pH, temperature, light) is advancing. These materials could enable multi-functional columns that capture, wash, and elute under different conditions without the need for multiple column types. Additionally, improvements in resin bead design using computational modeling promise to further reduce diffusion limitations, especially for large biomolecules.

Integration with Continuous Polishing and Formulation

Future facilities will likely operate as fully continuous trains from cell culture through to purified drug substance. Continuous chromatography will be seamlessly integrated with continuous capture, viral inactivation, polishing, and final formulation steps. This vision is already being realized at pilot scale by several major biopharma companies and will become more common as regulatory experience grows.

Broader Adoption for Biosimilars and Emerging Modalities

Biosimilar manufacturers, under pressure to reduce costs and speed time-to-market, are early adopters of continuous chromatography. Similarly, emerging modalities such as mRNA, siRNA, gene therapy vectors, and cell therapies can benefit from the gentle and efficient purification that continuous systems offer. For example, adeno-associated virus (AAV) vectors used in gene therapy are sensitive to shear and require rapid processing to maintain potency — conditions well suited to continuous chromatography.

Conclusion

Continuous chromatography has moved from an academic concept to a practical, value-adding technology that is transforming biologics purification. Recent advances in resin design, automation, modularization, and process integration have made continuous systems faster, more reproducible, and more cost-effective than their batch predecessors. As the biopharmaceutical industry embraces continuous manufacturing, the ability to purify biologic drugs more efficiently will directly impact patient access and global health security. The future of biologics purification is continuous, and the technologies described here are leading the way.

FDA Guidance on Continuous Manufacturing outlines regulatory expectations for these innovative processes. For practical implementation insights, resources from Cytiva’s Continuous Chromatography Knowledge Center and case studies from Sartorius are excellent references.